Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.

As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid ...

Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.